Naglazyme (Galsulfase)

Galsulfase is a recombinant form of human N‑acetylgalactosamine‑4‑sulfatase. When administered intravenously, it enters cells and reaches lysosomes, where it restores the enzymatic step that removes sulfate groups from dermatan sulfate, allowing normal degradation of this glycosaminoglycan.

The dosing regimen for Naglazyme is individualized. A qualified prescriber determines the appropriate dose and infusion schedule based on the patient’s weight, disease severity, and clinical response.

The safety of Naglazyme in pregnancy and lactation has not been established. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and decisions are made in consultation with a specialist.

To request Naglazyme, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, cold‑chain shipping details, and necessary import documentation.

Naglazyme is the only enzyme replacement therapy specifically approved for MPS VI, directly supplying the deficient N‑acetylgalactosamine‑4‑sulfatase. Alternative approaches, such as hematopoietic stem cell transplantation, address the disease differently and carry distinct risk‑benefit profiles.

Naglazyme must be stored refrigerated at 2‑8 °C. Keep the vial in its original packaging, protect it from light, and avoid freezing or shaking the solution. Do not use the product if it has been exposed to temperatures outside this range.

Naglazyme is given as an intravenous infusion. The solution is diluted according to the prescribing information and administered over a period defined by the treating physician, typically in a clinical setting equipped for infusion monitoring.

Serious risks include severe hypersensitivity reactions such as anaphylaxis, significant liver enzyme elevations, pulmonary hypertension, and renal impairment. Patients should be closely monitored during and after infusions for any signs of these events.

Naglazyme is contraindicated in individuals with a known hypersensitivity to Galsulfase or any excipients in the formulation. Caution is also advised for patients with uncontrolled cardiac disease, severe liver dysfunction, or active infections.